Adial Pharmaceuticals Inc
NASDAQ:ADIL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Shenzhen Sunlord Electronics Co Ltd
SZSE:002138
|
CN |
Adial Pharmaceuticals Inc
Intangible Assets
Adial Pharmaceuticals Inc
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Adial Pharmaceuticals Inc
NASDAQ:ADIL
|
Intangible Assets
$2.8k
|
CAGR 3-Years
-82%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Intangible Assets
$50.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Intangible Assets
$19.1B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
30%
|
|
|
Pfizer Inc
NYSE:PFE
|
Intangible Assets
$53.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
14%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Intangible Assets
$26.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
2%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Intangible Assets
$6.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
3%
|
|
Adial Pharmaceuticals Inc
Glance View
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. The company is headquartered in Charlottesville, Virginia and currently employs 16 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. AD04 is used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The firm is also developing adenosine analogs for the treatment of pain and other disorders through its wholly owned subsidiary, Purnovate, Inc.
See Also
What is Adial Pharmaceuticals Inc's Intangible Assets?
Intangible Assets
2.8k
USD
Based on the financial report for Dec 31, 2025, Adial Pharmaceuticals Inc's Intangible Assets amounts to 2.8k USD.
What is Adial Pharmaceuticals Inc's Intangible Assets growth rate?
Intangible Assets CAGR 5Y
-22%
Over the last year, the Intangible Assets growth was -18%. The average annual Intangible Assets growth rates for Adial Pharmaceuticals Inc have been -82% over the past three years , -22% over the past five years .
